Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex ( ($VERX) ) has shared an update. On October 21, 2025, Vertex announced the retirement of David DeStefano as CEO, effective November 10, ...

Christopher Young to Succeed David DeStefano as Vertex’s President and Chief Executive OfficerLeadership Transition to Occur on November 10, ...

Vertex, Inc. (NASDAQ: VERX) announced CEO David DeStefano's retirement and succession plan. Christopher Young chosen as new ...

A former executive at Microsoft, McAfee and Cisco becomes the fourth CEO in Vertex's 47-year history.

Vertex said Tuesday that David DeStefano is retiring as president and chief executive, effective Nov. 10. The company added that its board has named Christopher Young as its new president and CEO, ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new non-opioid painkiller while recovering from a serious injury. Tatum ruptured his ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim ...